Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retina and anterior neural fold homeobox protein 2 (RAX2) is a homeodomain-containing transcription factor predominantly expressed in the outer and inner nuclear layers of the retina. RAX2 regulates photoreceptor gene expression by acting as a coactivator, often forming complexes with other transcription factors such as CRX and NRL. It is critical for retinal development, particularly through its influence on the expression of key developmental genes like PAX6 and SOX2. Mutations in the RAX2 gene have been associated with inherited retinal disorders, including autosomal dominant cone-rod dystrophy (CORD11), autosomal recessive retinitis pigmentosa (ARRP), and age-related macular degeneration type 6 (ARMD6). RAX2 mutations disrupt normal photoreceptor cell function and differentiation, leading to progressive vision loss. To date, no approved drugs directly target RAX2.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retina and anterior neural fold homeobox protein 2 (RAX2).